Archives of Clinical Infectious Diseases

Published by: Kowsar

Reduction in Prevalence of Hepatitis B Surface Antigen Among Intravenous Drug Users in Tehran Drop-in-Centers

Tahmineh kandelouei 1 , Seyed Masoud Hosseini 1 , Latif Gachkar 2 , Hossein Keyvani 3 , Foad Davoodbeglou 4 and Maryam Vaezjalali 5 , *
Authors Information
1 Department of Microbiology, Faculty of Biological Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
3 Department of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, IR Iran
4 Department of Immunology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
5 Department of Microbiology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Archives of Clinical Infectious Diseases: April 24, 2013, 8 (2); e15531
  • Published Online: April 17, 2013
  • Article Type: Research Article
  • Received: January 5, 2013
  • Revised: March 2, 2013
  • Accepted: March 29, 2013
  • DOI: 10.5812/archcid.15531

To Cite: kandelouei T, Hosseini S M, Gachkar L, Keyvani H, Davoodbeglou F, et al. Reduction in Prevalence of Hepatitis B Surface Antigen Among Intravenous Drug Users in Tehran Drop-in-Centers, Arch Clin Infect Dis. 2013 ; 8(2):e15531. doi: 10.5812/archcid.15531.

Abstract
Copyright © 2013, Infectious Diseases and Tropical Medicine Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Lugoboni F, Quaglio G, Civitelli P, Mezzelani P. Bloodborne viral hepatitis infections among drug users: the role of vaccination. Int J Environ Res Public Health. 2009; 6(1): 400-13[DOI][PubMed]
  • 2. Schleicher S, Schieffer M, Jurgens S, Wehner HD, Flehmig B. Evidence of multiple hepatitis virus infections in autopsied materials of intravenous drug addicts. Ig Sanita Pubbl. 2005; 61(5): 435-50[PubMed]
  • 3. Tofigi H, Ghorbani M, Akhlaghi M, Yaghmaei A, Mostafazadeh B, Farzaneh E, et al. Incidence of hepatitis B and HIV virus at cadaver of IV drug abusers in Tehran. Acta Med Iran. 2011; 49(1): 59-63[PubMed]
  • 4. Levine OS, Vlahov D, Koehler J, Cohn S, Spronk AM, Nelson KE. Seroepidemiology of hepatitis B virus in a population of injecting drug users. Association with drug injection patterns. Am J Epidemiol. 1995; 142(3): 331-41[PubMed]
  • 5. Maher L, Chant K, Jalaludin B, Sargent P. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia. J Gastroenterol Hepatol. 2004; 19(10): 1114-20[DOI][PubMed]
  • 6. Butler T, Boonwaat L, Hailstone S, Falconer T, Lems P, Ginley T, et al. The 2004 Australian prison entrants' blood-borne virus and risk behaviour survey. Aust N Z J Public Health. 2007; 31(1): 44-50[PubMed]
  • 7. Seyed Alinaghi SA, Kheirandish P, Karami N, Salem S, Shirzad H, Jahani MR, et al. High prevalence of chronic hepatitis B infection among injection drug users in Iran: the need to increase vaccination of adults at risk. Acta Med Iran. 2010; 48(1): 58-60[PubMed]
  • 8. Forouzanfar MH, Mohammad K, Majdzadeh R, Malekzadeh R, Abou AlhasaniF, Mohammadnejad M, et al. Effectiveness of adolescents'immunization against hepatitis B on burden of the disease in Iran. Hakim. 2006; 9(2): 1-1
  • 9. Razzaghi EM, Movaghar AR, Green TC, Khoshnood K. Profiles of risk: a qualitative study of injecting drug users in Tehran, Iran. Harm Reduct J. 2006; 3: 12[DOI][PubMed]
  • 10. Karimi A. P.483 Seroprevalence of HBV, HCV and HIV among intravenous drug users in Iran. J Clin Virol. 2006; 36
  • 11. Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM, et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy. 2007; 18(5): 359-63[DOI][PubMed]
  • 12. Mir-Nasseri SM, Poustchi H, Nasseri-Moghadam S, Nouraie SM, Tahaghoghi S, Afshar P, et al. HCV in intravenous drug users. Govaresh. 2012; 10(2): 80-6
  • 13. Alavian SM. Control of hepatitis C in Iran: vision and missions. Hepat Mon. 2007; 7(2): 57-8
  • 14. Alavi SM, Etemadi A. HIV/HBV, HIV/HCV and HIV/HTLV-1 co infection among injecting drug user patients hospitalized at the infectious disease ward of a training hospital in Iran. Pakistan J Med Sci. 2007; 23(4): 510
  • 15. Zali MR, Aghazadeh R, Nowroozi A, Amir-Rasouly H. Anti-HCV antibody among Iranian IV drug users: is it a serious problem. Arch Iran Med. 2001; 4(3): 115-9
  • 16. Alizadeh AHM, Alavian SM, Jafari K, Yazdi N. Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan-Iran. World J Gastroenterol. 2005; 11(26): 4085
  • 17. Amin-Esmaeili M, Rahimi-Movaghar A, Razaghi EM, Baghestani AR, Jafari S. Factors Correlated With Hepatitis C and B Virus Infections Among Injecting Drug Users in Tehran, IR Iran. Hepat Mon. 2012; 12(1): 23-31[DOI][PubMed]
  • 18. Daneshmand D, Nokhodian Z, Adibi P, Ataei B. Risk prison and hepatitis B virus infection among inmates with history of drug injection in Isfahan, Iran. Sci World J. 2013; 2013
  • 19. Khodadadizadeh A, Esmaeili NA, Hossieni SH, Shabani Sharbabaki Z. The prevalence of HIV, HBV and HCV in narcotic addicted persons referred to the out patient clinic of rafsanjan university of medical sciences in 2003. J Rafsanjan Univ Med Sci. 2006; 5(1): 23-30
  • 20. Nikkhooy A, Nikkhooy M, Saadati N. Determination of relative frequency of HBS Ag, HCV and HIV antibodies serum markers among admitted intravenous drug users in infectious disease wardof Razi Hospital in Ahvaz, 2004-2005. J Health Res. 2012; 1(1): 26-33
  • 21. Imani R, karymi A, Kasaeeian N. The relevance of related-risk behaviors and seroprevalence of HBV, HCV and HIV infection in intravenous drug users from Shahrekord, Iran, 2004. Shahrekord U Med Sci J. 2006; 8(1): 58-62
  • 22. Nokhodian Z, Yazdani MR, Yaran M, Shoaei P, Mirian M, Ataei B, et al. Prevalence and Risk Factors of HIV, Syphilis, Hepatitis B and C Among Female Prisoners in Isfahan, Iran. Hepat Mon. 2012; 12(7): 442-7[DOI][PubMed]
  • 23. Kassaian N, Ataei B, Yaran M, Babak A, Shoaei P. Hepatitis B and C among women with illegal social behavior in Isfahan, Iran: Seroprevalence and associated factors. Hepat Mon. 2011; 11(5): 368-71[PubMed]
  • 24. Khosravani A, Sarkari B, Negahban H, Sharifi A, Toori MA, Eilami O. Hepatitis B Infection among high risk population: a seroepidemiological survey in Southwest of Iran. BMC Infect Dis. 2012; 12: 378[DOI][PubMed]
  • 25. Zali MR, Kazem M, Farhadi A, Masjedi MR, Zargar A, Nowroozi A. Epidemiology of hepatitis B in the Islamic Republic of Iran. Relation. 1996; 2(2): 290-8
  • 26. Alavi SM, Behdad F. Seroprevalence study of hepatitis C and Hepatitis B virus among hospitalized intravenous drug users in Ahvaz, Iran (2002-2006). Hepat Mon. 2010; 10(2): 101-4[PubMed]
  • 27. Mir-Nasseri MM, Mohammadkhani A, Tavakkoli H, Ansari E, Poustchi H. Incarceration is a major risk factor for blood-borne infection among intravenous drug users: Incarceration and blood borne infection among intravenous drug users. Hepat Mon. 2011; 11(1): 19-22[PubMed]
  • 28. Backmund M, Meyer K, Schuetz C, Reimer J. Factors associated with exposure to hepatitis B virus in injection drug users. Drug Alcohol Depend. 2006; 84(2): 154-9[DOI][PubMed]
  • 29. Mansson AS, Moestrup T, Nordenfelt E, Widell A. Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scand J Infect Dis. 2000; 32(3): 253-8[PubMed]
  • 30. Ruan Y, Qin G, Yin L, Chen K, Qian HZ, Hao C, et al. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study. AIDS. 2007; 21 Suppl 8-46[DOI][PubMed]
  • 31. Miller ER, Hellard ME, Bowden S, Bharadwaj M, Aitken CK. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia. J Infect. 2009; 58(5): 375-82[DOI][PubMed]
  • 32. Zamani S, Kihara M, Gouya MM, Vazirian M, Ono-Kihara M, Razzaghi EM, et al. Prevalence of and factors associated with HIV-1 infection among drug users visiting treatment centers in Tehran, Iran. AIDS. 2005; 19(7): 709-16[PubMed]
  • 33. Merat S, Malekzadeh R, Rezvan H, Khatibian M. Hepatitis B in Iran. Arch Iranian Med. 2000; 3(4): 192-201
  • 34. Farhat A, Khademi G, Mazlouman SJ. The prevalence of hepatitis B carrier state in Khorassan province of Iran. Saudi Med J. 2003; 24(5): 549-51[PubMed]
  • 35. Sharif M, Sherif A, Sayyah M. Frequency of HBV, HCV and HIV infections among hospitalized injecting drug users in Kashan. Indian J Sex Transm Dis. 2009; 30(1): 28-30[DOI][PubMed]
  • 36. Stief AC, Martins RM, Andrade SM, Pompilio MA, Fernandes SM, Murat PG, et al. Seroprevalence of hepatitis B virus infection and associated factors among prison inmates in state of Mato Grosso do Sul, Brazil. Rev Soc Bras Med Trop. 2010; 43(5): 512-5[PubMed]
  • 37. Nguyen VTT, Dore GJ. Prevalence and epidemiology of hepatitis B. All You Wanted to Know About. 2001; : 13
  • 38. Shapatava E, Nelson KE, Tsertsvadze T, del Rio C. Risk behaviors and HIV, hepatitis B, and hepatitis C seroprevalence among injection drug users in Georgia. Drug Alcohol Depend. 2006; 82 Suppl 1-8[PubMed]
  • 39. Vassilev ZP, Hagan H, Lyubenova A, Tomov N, Vasilev G, Krasteva D, et al. Needle exchange use, sexual risk behaviour, and the prevalence of HIV, hepatitis B virus, and hepatitis C virus infections among Bulgarian injection drug users. Int J STD AIDS. 2006; 17(9): 621-6[DOI][PubMed]
  • 40. Fuglsang T, Fouchard JR, Ege PP. [Prevalence of HIV and hepatitis B and C among drug addicts in the city of Copenhagen]. Ugeskr Laeger. 2000; 162(27): 3860-4[PubMed]
  • 41. Samuel MC, Doherty PM, Bulterys M, Jenison SA. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiol Infect. 2001; 127(3): 475-84[PubMed]
  • 42. Christensen PB, Krarup HB, Niesters HG, Norder H, Georgsen J. Prevalence and incidence of bloodborne viral infections among Danish prisoners. Eur J Epidemiol. 2000; 16(11): 1043-9[PubMed]
  • 43. Shirin T, Ahmed T, Iqbal A, Islam M, Islam MN. Prevalence and risk factors of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infections among drug addicts in Bangladesh. J Health Popul Nutr. 2000; 18(3): 145-50[PubMed]
  • 44. Todd CS, Abed AM, Strathdee SA, Scott PT, Botros BA, Safi N, et al. HIV, hepatitis C, and hepatitis B infections and associated risk behavior in injection drug users, Kabul, Afghanistan. Emerg Infect Dis. 2007; 13(9): 1327-31[DOI][PubMed]
  • 45. Altaf A, Shah SA, Zaidi NA, Memon A, Nadeem ur R, Wray N. High risk behaviors of injection drug users registered with harm reduction programme in Karachi, Pakistan. Harm Reduct J. 2007; 4: 7[DOI][PubMed]
  • 46. Mirahmadizadeh A, Kadivar M, Hemmati A, Javadi A. Infection with HIV and hepatitis C and B viruses among injecting drug users in Shiraz, Southern Iran 2004;
  • 47. Javadi AA, Avijgan M, Hafizi M. Prevalence of HBV and HCV infections and associated risk factors in addict prisoners. Iranian J Public Health. 2006; 35(4)
  • 48. Rahimi-Movaghar A, Razaghi EM, Sahimi-Izadian E, Amin-Esmaeili M. HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran. Int J Infect Dis. 2010; 14(1)-33[DOI][PubMed]
  • 49. Khani M, Vakili MM. Prevalence and risk factors of HIV, hepatitis B virus and hepatitis C virus infections in drug addicts among Zanjan prisoners. Arch Iranian Med. 2003; 6(1): 1-4
  • 50. Aminzade Z, Aghazadeh Sarhangi Poor K. [Seroepidemiology of HIV,HBV, HCV and syphilis among intravenous drug user hospitilized in Loghman Hospital,Tehran, Iran]. J Iran Med Microbilogy. 2007; 1(3): 53-6
  • 51. Taeri K, Kassaeian N, Fadaei Nobari R, Ataei B. [A survay on prevalence of HBV, HCV and main risk factors among HIV positive intravenous drug users in Esfahan]. Esfahan Med Sch J. 2009; 26(90)
  • 52. Mohammad K, Asgari F, Gooya MM, Fotoohi A, Yoosefi A. [HBV in Iran prisons and it's correlation with addiction]. Payesh J. 2008; 7(3): 279-86
  • 53. Esteghamati A, Keshtkar AA, Nadjafi L, Gouya MM, Salaramoli M, Roshandel G, et al. Hepatitis B vaccination coverage among Iranian children aged 15-26 months in 2006. East Mediterr Health J. 2011; 17(2): 93-100[PubMed]
  • 54. Zali MR, Mohammad K, Noorbala AA, Noorimayer B, Shahraz S. Rate of hepatitis B seropositivity following mass vaccination in the Islamic Republic of Iran. East Mediterr Health J. 2005; 11(1-2): 62-7[PubMed]
  • 55. Islamic republic of Iran country report on monitoring of the united nations, general assembly special session on HIV and AIDS. National AIDS Committee Secretariat. 2010;
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments